Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc.  ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration combines Alpha Fusion's leading role in At-211 drug discovery and early clinical work in Japan, with Curadh's global expertise in radiopharmaceutical development.  

The Joint Venture will focus on clinical development of lead products in the US as well as broadly developing a pipeline of At-211 products.  The partners announced their plans at the World Astatine Community Meeting. The therapeutic potential for At-211 by the Joint Venture was highlighted in talks given by the companies' scientific/clinical founders.

Tadashi Watabe, M.D., Ph.D., FANMB, Department of Radiology, Graduate School of Medicine, University of Osaka presented "Progress Update on Astatine Clinical Trials in Osaka" as Principal Investigator of the studies.

Alison Armour, MD., FRCP., FRCR, Founder and CMO of Curadh talked on "Why Astatine Will Be Important for The Future of Molecularly Targeted Radiopharmaceuticals"

"Alpha Fusion is advancing its pipeline and building a highly efficient supply chain for At-211 using cyclotrons and GMP manufacturing in collaboration with partners across the globe" stated CEO Sunao Fujioka. "Our strategic partnership with Curadh, who has deep expertise in radiopharmaceuticals, will significantly accelerate expansion into the US and global market".

"This strategic partnership with Alpha Fusion's foundational At-211 drug discovery platform and first-in-human studies strengthens our position in next-generation radiopharmaceuticals" added Glenn Kazo, CEO of Curadh.  "Astatine's unique properties as a halogen emitter with a short half-life makes it one of the most promising alphas for molecularly targeted cancer therapy"